RxDoctor Payments Data

Regina Frants, MD

Pulmonary Disease · Johnson City, NYNPI 1891780979

Payments from drug & device makers

$20,713in general payments, 2019–2025

Across 926 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • GSK$4K
  • Boehringer Ingelheim$2K
  • Sanofi$1K
  • Regeneron Healthcare Solutions, Inc.$857
  • Grifols USA, LLC$848
  • plus $7K from 37 others

What the payments were for

  • Food & beverage$20,46499%
  • Education$2501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,713 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$94,999
Medicare patients
367
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor25$412,580
Trelegy ElliptaFluticasone/Umeclidin/Vilanter471$382,567
OfevNintedanib Esylate27$360,260
OpsumitMacitentan12$151,198
Breztri AerosphereBudesonide/Glycopyr/Formoterol141$134,743
Spiriva RespimatTiotropium Bromide143$128,971
Dupixent PenDupilumab34$121,126
Breo ElliptaFluticasone/Vilanterol164$95,681
Qvar RedihalerBeclomethasone Dipropionate158$74,863
SymbicortBudesonide/Formoterol Fumarate184$74,658
Incruse ElliptaUmeclidinium Bromide130$71,838
DuleraMometasone/Formoterol61$50,928
Spiriva HandihalerTiotropium Bromide47$48,286
Advair HfaFluticasone Propion/Salmeterol74$40,201
Arnuity ElliptaFluticasone Furoate113$37,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta$3,723$612,708915 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$1,972$519,184219 claims
Grifols USA, LLCProlastin C$848$412,58025 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$5,205$235,406408 claims
Actelion Pharmaceuticals US, Inc.Opsumit$521$151,19812 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$179$74,863158 claims
MerckDulera$406$50,92861 claims
Johnson & JohnsonXarelto$495$8,33715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Johnson City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →